US judge recommends terminating US Xyrem antitrust litigation
( October 30, 2025, 01:01 GMT | Official Statement) -- MLex Summary: Following class settlements, a US judge recommended terminating multidistrict litigation in which Jazz, Hikma and other pharmaceutical companies were alleged to have executed an anticompetitive scheme to impair and delay competition in the market for generic Xyrem, a sodium oxybate drug used to treat narcolepsy. In December 2020, the Judicial Panel on Multidistrict Litigation centralized all pending end-payor class actions to the US Northern District of California for pretrial proceedings.See order. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.